News on immunohistochemistry and other tissue-based testing methods.
Patients with genomic profiling test results showing potential inherited cancer gene variants will be able to undergo genetic counseling and follow-up germline testing.
The test uses prognostic markers to group women based on their risk of 10-year recurrence of ductal carcinoma in situ.
Scale Venture Partners led the Series B round with participation from Hitachi Ventures. Proscia raised $8.3 million in its Series A round in 2018.
The deal provides clinicians with digital access to Flagship Bio's TissueInsight via Inspirata's Dynamyx digital pathology product.
Promega will develop its microsatellite instability assay as a companion diagnostic for Incyte's anti-PD-1 drug candidate retifanlimab in endometrial cancer.
